Ovid Therapeutics Ownership | Who Owns Ovid Therapeutics?

Overview Forecast RevenueFinancials Chart

Ovid Therapeutics Ownership Summary

Ovid Therapeutics is owned by 199.97% institutional investors, 6.72% insiders. Ra capital management is the largest institutional shareholder, holding 14.53% of OVID shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 5.73% of its assets in Ovid Therapeutics shares.

OVID Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Ovid Therapeutics	199.97%	6.72%	-106.70%
Sector	Healthcare Stocks	244.37%	12.11%	-156.48%
Industry	Biotech Stocks	379.01%	11.75%	-290.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ra capital management	10.71M	14.53%	$23.79M
Janus henderson group	10.71M	14.53%	$23.73M
Affinity asset advisors	10.64M	14.42%	$23.61M
Eventide asset management	9.92M	13.45%	$22.02M
Takeda pharmaceutical	7.53M	10.59%	$9.79M
Adage capital partners gp	6.16M	8.36%	$13.68M
Balyasny asset management	5.53M	7.50%	$12.28M
Saturn v capital management	4.17M	5.65%	$9.25M
Blackrock	3.99M	5.65%	$3.07M
Federated hermes	3.57M	4.84%	$7.93M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Takeda pharmaceutical	7.53M	59.82%	$9.79M
Saturn v capital management	4.17M	1.68%	$9.25M
Propel bio management	921.46K	1.28%	$2.04M
Affinity asset advisors	10.64M	1.22%	$23.61M
Rosalind advisors	1.11M	0.99%	$2.46M
Sphera funds management	1.62M	0.57%	$3.60M
Ikarian capital	2.89M	0.52%	$6.43M
Sio capital management	1.25M	0.40%	$2.78M
Verdad advisers, lp	151.92K	0.38%	$337.26K
Eventide asset management	9.92M	0.36%	$22.02M

Top Buyers

Holder	Shares	% Assets	Change
Janus henderson group	10.71M	0.01%	10.71M
Eventide asset management	9.92M	0.36%	5.63M
Balyasny asset management	5.53M	0.02%	5.21M
Affinity asset advisors	10.64M	1.22%	3.49M
Adage capital partners gp	6.16M	0.02%	2.67M

Top Sellers

Holder	Shares	% Assets	Change
Ecor1 capital	-	-	-6.12M
Bvf inc/il	-	-	-3.85M
Siren	-	-	-2.85M
Point72 asset management	1.32M	0.00%	-2.23M
Blue owl capital lp	-	-	-1.90M

New Positions

Holder	Shares	% Assets	Change	Value
Janus henderson group	10.71M	0.01%	10.71M	$23.73M
Sphera funds management	1.62M	0.57%	1.62M	$3.60M
Rosalind advisors	1.11M	0.99%	1.11M	$2.46M
Silverarc capital management	1.00M	0.23%	1.00M	$2.22M
Propel bio management	921.46K	1.28%	921.46K	$2.04M

Sold Out

Holder	Change
Newedge advisors	-4.00
Sound income strategies	-6.00
Ifp advisors	-8.00
True wealth design	-8.00
Frazier financial advisors	-10.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	135	23.85%	147,450,458	40.34%	199	0.98%	82	32.26%	27	35.00%
Mar 31, 2026	106	17.78%	97,413,114	57.44%	132	1.74%	60	36.36%	19	-24.00%
Dec 31, 2025	37	-55.95%	12,969,774	-64.18%	18	0.70%	15	-64.29%	9	-62.50%
Sep 30, 2025	26	-62.86%	6,077,081	-83.10%	8	0.33%	13	-60.61%	8	-61.90%
Jun 30, 2025	69	-15.85%	35,963,757	-7.47%	2,877	297.56%	34	17.24%	21	-25.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	9.92M	5.73%	5.63M
Federated Hermes Kaufmann Small Cap Grow	7.74M	4.47%	2.38M
Federated Hermes Kaufmann Small Cap A	5.95M	3.44%	2.38M
Vanguard Morn Total Stk Mkt Idx Investor	5.65M	3.27%	1.82M
Vanguard Total Stock Mkt Idx Inv	5.65M	3.27%	1.82M
Vanguard MStar Total Stk Mkt Idx Invest	5.65M	3.06%	-
State Street® SPDR® S&P® Biotech ETF	4.84M	2.80%	11.12K
Vanguard US Total Market Shares ETF	1.79M	2.52%	-
iShares Russell 2000 ETF	3.80M	2.20%	-67.49K
Kennedy Micro Cap	1.04M	1.46%	-64.12K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 23, 2026	ALEXANDER MARGARET A.	President and CEO	Sell	$16.90K
Feb 23, 2026	Rona Jeffrey A	CBFO	Sell	$12.38K
Dec 11, 2025	LEVIN JEREMY M	CEO	Buy	-
Dec 11, 2025	LEVIN JEREMY M	CEO	Buy	$66.27K
Dec 11, 2025	LEVIN JEREMY M	CEO	Buy	$49.70K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	-
2026 Q2	-	-
2026 Q1	-	2
2025 Q4	3	-
2025 Q1	1	2

OVID Ownership FAQ

Who Owns Ovid Therapeutics?

Ovid Therapeutics shareholders are primarily institutional investors at 199.97%, followed by 6.72% insiders and -106.69% retail investors. The average institutional ownership in Ovid Therapeutics's industry, Biotech Stocks , is 379.01%, which Ovid Therapeutics falls below.

Who owns the most shares of Ovid Therapeutics?

Ovid Therapeutics’s largest shareholders are Ra capital management (10.71M shares, 14.53%), Janus henderson group (10.71M shares, 14.53%), and Affinity asset advisors (10.64M shares, 14.42%). Together, they hold 43.49% of Ovid Therapeutics’s total shares outstanding.

Does Blackrock own Ovid Therapeutics?

Yes, BlackRock owns 5.65% of Ovid Therapeutics, totaling 3.99M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.07M$. In the last quarter, BlackRock decreased its holdings by -203K shares, a -4.84% change.

Who is Ovid Therapeutics’s biggest shareholder by percentage of total assets invested?

Takeda pharmaceutical is Ovid Therapeutics’s biggest shareholder by percentage of total assets invested, with 59.82% of its assets in 7.53M Ovid Therapeutics shares, valued at 9.79M$.

Who is the top mutual fund holder of Ovid Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Ovid Therapeutics shares, with 5.73% of its total shares outstanding invested in 9.92M Ovid Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools